7th International Leukocyte Signal Transduction Conference

描述(申请人提供)：适当的免疫反应依赖于不同白细胞和其他细胞类型及其可溶性产物之间的复杂相互作用，以及许多受体之间的广泛相互作用，这些受体传递激活或抑制信号，导致诱导细胞特有的基因程序、分化、增殖和获得效应器功能。放松免疫反应可能会导致有害的结果，自身免疫性疾病的发展就是一个很好的例子。导致炎症和自身免疫发展的异常机制在很大程度上是通过对小鼠的基因操作来阐明的，这导致了对潜在信号机制的重大洞察。因此，信号通路在特定步骤上的基因改变可以预防或诱导自身免疫和其他免疫性疾病的发展。然而，小型科学会议允许密集的互动和富有成效的讨论，同时将致力于研究白细胞信号通路的基本方面和这些途径的临床意义(包括相关疾病模型)的科学家聚集在一起，这样的会议还很少。请求提供资金，以支持将于2013年9月8日至13日在希腊科斯举行的第七届国际白细胞信号转导会议。这是2000年发起的一系列类似会议中的最新一次。预计将有大约80名与会者参加这次会议，会议将汇集致力于白细胞信号通路的基本方面、相关动物疾病模型以及这些通路的临床意义的科学家，他们正在利用尖端技术解决基本的免疫学问题。特邀教员由~24名国际知名科学家组成，他们都是相关研究领域的公认专家。处于职业生涯早期形成阶段的科学家将优先参加一次演讲。该会议的具体目标是：1.通过重点关注自2011年举行的上一次(第6次)会议以来产生的重大新发现和发现，扩展和继续以前的六次高产的白细胞信号转导会议。2.召集国际知名科学家，他们是白细胞信号转导和白细胞信号通路对炎症、自身免疫和传染病等疾病影响的专家，以介绍和讨论最新的相关研究。3.让处于职业生涯早期阶段的科学家，即博士后研究员和研究生，特别是代表少数群体或来自发展中国家的科学家，有机会介绍自己的工作，并从与领先科学家的密切、一对一的互动中受益，从而提供教育经验和致力于生物医学研究事业的动力。本次会议将提供有关所涵盖主题的最新信息，并将促进致力于白细胞信号基本方面的科学家与研究动物或人类炎症性和自身免疫性疾病以及血液病的科学家之间的想法分享和合作。

DESCRIPTION (provided by applicant): A proper immune response depends on complex interactions between different leukocytes and other cell types and their soluble products, and on an extensive crosstalk among many receptors, which transduce activating or inhibitory signals leading to induction of cell-specific gene programs, differentiation, proliferation, and acquisitio of effector functions. A deregulated immune response can lead to harmful results, the development of autoimmune diseases being a prime example. Aberrant mechanisms that lead to development of inflammation and autoimmunity have been elucidated to a large degree by genetic manipulation of mice, which led to significant insights into the underlying signaling mechanisms. Thus, genetic alteration of signaling pathways at defined steps can prevent or induce the development of autoimmunity and other immunological diseases. However, small scientific meetings that allow intensive interactions and fruitful discussions and, at the same time, bring together scientists working on fundamental aspects of leukocyte signaling pathways and on the clinical implications of these pathways (including relevant disease models) are far and few between. Funds are requested to support The 7th International Leukocyte Signal Transduction Conference to be held in Kos, Greece, on September 8-13, 2013. This is the latest in a series of similar meetings initiated in 2000. The meeting, with ~80 anticipated participants, will bring together scientists working on fundamental aspects of leukocyte signaling pathways, related animal disease models, and clinical implications of these pathways, who is cutting edge technologies to address fundamental immunological problems. The invited faculty consists of ~24 internationally known scientists who are recognized experts in relevant research areas. Scientists at the early, formative stage of their career will be given priority in participation an presentation. The Specific Aims of the Conference are to: 1. Extend and continue six previous, highly productive Leukocyte Signal Transduction Conferences, by focusing on major new discoveries and findings generated since the previous (6th) Conference held in 2011. 2. Bring together internationally known scientists, who are experts in leukocyte signal transduction and the disease implications of leukocyte signaling pathways to, e.g., inflammation, autoimmunity, and infectious disease, in order to present and discuss the most up-to-date relevant research. 3. Give scientists at an early stage of their career, i.e., postdoctoral research fellows and graduate students, particularly those representing minority groups or coming from developing countries, an opportunity to present their own work and to benefit from close, one-on-one interactions with leading scientists, thereby providing an educational experience and a motivation to commit themselves to a biomedical research career. This conference will provide most up-to-date information on the covered topics, and will stimulate sharing of ideas and collaborations between scientists working on basic aspects of leukocyte signaling and those studying animal or human inflammatory and autoimmune diseases and hematopoietic cancers.